吉祥坊登录

Shanghai, China——As a clinical demonstration application research topic for innovative medical devices, the post-marketing clinical study of Minos™ Abdominal Aortic Stent-Graft and Delivery System, which was co-declared by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec™”), Zhongshan Hospital of Fudan University and Renji Hospital of Shanghai Jiaotong University, was selected for the 2019 “Science and Technology Innovation Action Plan” project in the field of cooperation between industry, education, research and medicine in Shanghai.

According to the 13th Five-year Plan of Shanghai Science and Technology Innovation, Science and Technology Committee of Shanghai establish that 2019 “Science and Technology Innovation Action Plan” project in the field of cooperation between industry, education, research and medicine. These projects aim to promote the implementation of an innovation-driven development strategy and accelerate the construction of a globally influential science and technology innovation center. Research on the clinical demonstration application of innovative medical devices is one of the topics of the project. Its research goal is to complete the clinical demonstration application and re-evaluation research of innovative medical devices after listing, and form a product optimization plan.

Minos™ Abdominal Aortic Stent Graft and Delivery System（Minos™ Stent Graft System）, independently developed by Endovasctec™, gained NMPA approval on March 19, 2019 and CE certificate on September 12, 2019. The approval of Minos™ Stent Graft System will provide patients with complicated abdominal aortic anatomies with better solutions, especially benefiting patients with narrow and tortuous access arteries. The selected project was “Minos™ Abdominal Aortic Stent Graft and Delivery System Post-marketing Clinical Study”, will complete follow-up data analysis and statistics of the Minos™ ultra-low outer diameter abdominal aortic stent graft system and issue a clinical follow-up report. This project designed to provide a comprehensive and detailed evidence-based medical basis for the treatment of abdominal aortic aneurysms with the Minos™ stent graft system, providing more options for the treatment of abdominal aortic aneurysms.

Endovastec™ always pays attention to each user's personal feelings, and continuously innovates, and is committed to providing patients with aortic and peripheral vascular diseases with the best inclusive medical solutions that can save and reshape patients' lives or improve their quality of life, and make a contribution to society.